Cited by 1,730Renal cell carcinoma treatmentEar and Head TumorsCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D.R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N.H., Grossman, H.B., Brauch, H., Pomer, S., Brooks, J.D., Isaacs, W.B., Lerman, M.I., Zbar, B., Linehan, W.M.·1994·Nature Genetics

DOI 10.1038/ng0594-85

Open this paper in CoChat — free account

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Integrity signals

Registry

Crossref · 10.1038/ng0594-85

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Self-citation
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143
Diseases of the kidney
Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

Glenn, G.M., Choyke, P.L., Zbar, B. & Linehan, W.M. von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol. 4, 312–330 (1990).

Sorted by citations

Items 101–200 of 1,002

HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Maxwell, P. H., & Eckardt, K. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.193 · Cited by 288
Contemporary Epidemiology of Renal Cell Cancer
Chow, W., & Devesa, S. S. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e3181867628 · Cited by 282
Effect of Papillary and Chromophobe Cell Type on Disease-Free Survival After Nephrectomy for Renal Cell Carcinoma
Beck, S. D. W., Patel, M. I., Snyder, M. E., Kattan, M. W., Motzer, R. J., Reuter, V. E., & Russo, P. (2003) · Annals of Surgical Oncology · doi:10.1007/bf02524349 · Cited by 280
Genetic and Epigenetic Analysis of von Hippel-Lindau ( VHL ) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer
Banks, R. E., Tirukonda, P. S., Taylor, C., Hornigold, N., Astuti, D., Cohen, D. R., Maher, E. R., Stanley, A. J., Harnden, P., Joyce, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3074 · Cited by 276
Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells
Ried, K. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.11.1651 · Cited by 274
Ubiquitination: Friend and foe in cancer
Mansour, M. A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.06.001 · Cited by 280
Morphologic and Molecular Characterization of Renal Cell Carcinoma in Children and Young Adults
Bruder, E., Passera, O., Harms, D., Leuschner, I., Ladanyi, M., Argani, P., Eble, J. N., Struckmann, K., Schraml, P., & Moch, H. (2004) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000131558.32412.40 · Cited by 271
Localization of a CDKN2 gene in linkage group V of Xiphophorus fishes defines it as a candidate for the DIFF tumor suppressor
Kazianis, S., Gutbrod, H., Nairn, R. S., McEntire, B. B., Coletta, L. D., Walter, R. B., Borowsky, R. L., Woodhead, A. D., Setlow, R. B., Schartl, M., et al. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199807)22:3 · Cited by 60
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
Iliopoulos, O., Ohh, M., & Kaelin, W. G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11661 · Cited by 266
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene
Sidhar, S. K. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.9.1333 · Cited by 266
Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner, K., Moore, J. W., Jones, A., Taylor, C., Cuthbert-Heavens, D., Cheng, H., Leek, R., Gatter, K. C., Maxwell, P. H., Ratcliffe, P. J., et al. (2002) · PubMed · Cited by 265
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling
Wykoff, C. C., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204012 · Cited by 267
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 264
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Tran, H. T., Liu, Y., Zurita, A. J., Lin, Y., Baker-Neblett, K. L., Martin, A.-M., Figlin, R. A., Hutson, T. E., Sternberg, C. N., Amado, R. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70241-3 · Cited by 258
Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients
Lubensky, I. A., Pack, S., Ault, D. O., Vortmeyer, A. O., Libutti, S. K., Choyke, P. L., Walther, M. M., Linehan, W. M., & Zhuang, Z. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65563-0 · Cited by 258
Self-citation
MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism
Shroff, E. H., Eberlin, L. S., Dang, V. M., Gouw, A. M., Gabay, M., Adam, S. J., Bellovin, D. I., Tran, P. T., Philbrick, W. M., Garcia-Ocana, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507228112 · Cited by 255
Inherited genetic predisposition in breast cancer
Rebbeck, T. R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11+ · Cited by 73
Genetic Basis of Cancer of the Kidney
Linehan, W. M., Vasselli, J. R., Srinivasan, R., Walther, M. M., Merino, M. J., Choyke, P. L., Vocke, C. D., Schmidt, L. S., Isaacs, J. S., Glenn, G. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050013 · Cited by 251
Self-citation
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors
Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.89.2.2 · Cited by 244
VHL Tumor Suppressor Gene Alterations Associated With Good Prognosis in Sporadic Clear-Cell Renal Carcinoma
Yao, M. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.20.1569 · Cited by 250
Proteomic changes in renal cancer and co‐ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect
Unwin, R. D., Craven, R. A., Harnden, P., Hanrahan, S. J., Totty, N., Knowles, M. A., Ian Eardley, C., Selby, P. J., & Banks, R. E. (2003) · PROTEOMICS · doi:10.1002/pmic.200300464 · Cited by 246
Association of the P-Glycoprotein Transporter MDR1 C3435T Polymorphism with the Susceptibility to Renal Epithelial Tumors
Siegsmund, M. J., Brinkmann, U., Accent]ffeler, E. S. A., Weirich, G., Schwab, M. G., Eichelbaum, M. F., Fritz, P., Burk, O., Decker, J., Alken, P. M., et al. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000019412.87412.bc · Cited by 243
Self-citation
Targeted therapies for renal cell carcinoma
Posadas, E. M., Limvorasak, S., & Figlin, R. A. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.82 · Cited by 246
RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY
Walther, M. M., Choyke, P. L., Glenn, G. M., Lyne, J. C., Rayford, W., Venzon, D. J., & Linehan, W. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68930-6 · Cited by 243
Self-citation
Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeuticsPreprint
Linehan, W. M. (2012) · Genome Research · doi:10.1101/gr.131110.111 · Cited by 243
Self-citation
Kidney cancer
Vogelzang, N. J., & Stadler, W. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01041-1 · Cited by 239
Formation of the VHL–Elongin BC Tumor Suppressor Complex Is Mediated by the Chaperonin TRiC
Feldman, D. E., Thulasiraman, V., Ferreyra, R. G., & Frydman, J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80233-6 · Cited by 238
The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
Pause, A., Lee, S., Lonergan, K. M., & Klausner, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.993 · Cited by 237
Histone Methyltransferase Gene SETD2 Is a Novel Tumor Suppressor Gene in Clear Cell Renal Cell Carcinoma
Duns, G., van den Berg, E., van Duivenbode, I., Osinga, J., Hollema, H., Hofstra, R. M. W., & Kok, K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0120 · Cited by 246
Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
Whaley, J. M., Naglich, J. G., Gelbert, L. M., Hsia, Y. E., Lamiell, J. M., Green, J. S., Collins, D., Neumann, H. P., Laidlaw, J., & Li, F. P. (1994) · PubMed Central · Cited by 234
Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer
Hoque, M. O., Begum, S., Topaloglu, O., Jerónimo, C., Mambo, E., Westra, W. H., Califano, J. A., & Sidransky, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0799 · Cited by 233
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer
Xie, H., Valera, V., Merino, M. J., Amato, A. M., Signoretti, S., Linehan, W. M., Sukhatme, V. P., & Seth, P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1049 · Cited by 233
Self-citation
Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma
Kim, H. L., Seligson, D. B., Liu, X., Janzen, N. K., BUI, M. H. T., Yu, H., Shi, T., Figlin, R. A., Horvath, S., & Belldegrun, A. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0488 · Cited by 231
Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment Strategies
Shuch, B. M., Bratslavsky, G., Linehan, W. M., & Srinivasan, R. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0227 · Cited by 230
Self-citation
A second major native von Hippel–Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
Schoenfeld, A. R., Davidowitz, E. J., & Burk, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8817 · Cited by 236
Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma
Zhao, H., Ljungberg, B., Grankvist, K., Rasmuson, T., Tibshirani, R. J., & Brooks, J. D. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030013 · Cited by 227
Self-citation
Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy
Choueiri, T. K., Garcia, J. A., Elson, P. J., Khasawneh, M. K., Usman, S., Golshayan, A., Baz, R., Wood, L. S., Rini, B. I., & Bukowski, R. M. (2007) · Cancer · doi:10.1002/cncr.22827 · Cited by 227
aHIF: a Natural Antisense Transcript Overexpressed in Human Renal Cancer and During Hypoxia
Thrash-Bingham, C., & Tartof, K. D. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.143 · Cited by 226
Inferring Tree Models for Oncogenesis from Comparative Genome Hybridization Data
Desper, R., Jiang, F., Kallioniemi, O., Moch, H., Papadimitriou, C. H., & Schäffer, A. A. (1999) · Journal of Computational Biology · doi:10.1089/cmb.1999.6.37 · Cited by 228
Chromosomal Imbalances in Papillary Renal Cell Carcinoma
Jiang, F., Richter, J., Schraml, P., Bubendorf, L., Gasser, T., Sauter, G., Mihatsch, M. J., & Moch, H. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65734-3 · Cited by 224
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma
Frew, I. J., & Moch, H. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040306 · Cited by 230
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
Brauch, H. B., Weirich, G., Brieger, J., Glavač, D., Rödl, H., Eichinger, M., Feurer, M., Weidt, E. J., Puranakanitstha, C., Neuhaus, C., et al. (2000) · PubMed · Cited by 222
Self-citation
Hypermethylation of tumor suppressor genes in cancer
Herman, J. G. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0138 · Cited by 225
Novel approaches in the therapy of metastatic renal cell carcinoma
Lam, J. S., Leppert, J. T., Belldegrun, A. S., & Figlin, R. A. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0466-0 · Cited by 223
Landmarks in the diagnosis and treatment of renal cell carcinoma
Bhatt, J. R., & Finelli, A. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.194 · Cited by 222
Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species
Sudarshan, S., Sourbier, C., Kong, H.-S., Block, K., Romero, V. A. V., Yang, Y., Galindo, C., Mollapour, M., Scroggins, B., Goode, N., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00483-09 · Cited by 217
Self-citation
Von Hippel–Lindau disease
Chittiboina, P., & Lonser, R. R. (2015) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62702-5.00010-x · Cited by 223
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer
Vanharanta, S., Shu, W., Brenet, F., Hakimi, A. A., Heguy, A., Viale, A., Reuter, V. E., Hsieh, J. J.-D., Scandura, J. M., & Massagué, J. (2013) · Nature Medicine · doi:10.1038/nm.3029 · Cited by 215
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma
Schraml, P., Struckmann, K., Hatz, F., Sonnet, S., Kully, C., Gasser, T., Sauter, G., Mihatsch, M. J., & Moch, H. (2001) · The Journal of Pathology · doi:10.1002/path.1034 · Cited by 215
The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma
Nargund, A. M., Pham, C. G., Dong, Y., Wang, P. I., Osmangeyoglu, H. U., Xie, Y., Aras, Ö., Han, S., Oyama, T., Takeda, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.074 · Cited by 227
The von Hippel–Lindau Tumor Suppressor Gene
Kondo, K., & Kaelin, W. G. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5139 · Cited by 224
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
Prowse, A. H., Webster, A. R., Richards, F. M., Richard, S., Olschwang, S., Resche, F., Affara, N. A., & Maher, E. R. (1997) · Europe PMC (PubMed Central) · Cited by 215
Systemic Therapy for Non–clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis
Vera-Badillo, F., Templeton, A. J., Durán, I., Ocaña, A., Gouveia, P. D., Aneja, P., Knox, J. J., Tannock, I. F., Escudier, B. J., & Amir, E. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.010 · Cited by 214
Mutagenic and epigenetic effects of DNA methylation
Gonzalgo, M. L., & Jones, P. A. (1997) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(96)00047-6 · Cited by 216
THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE
Duffey, B. G., Choyke, P. L., Glenn, G. M., Grubb, R. L., Venzon, D. J., Linehan, W. M., & Walther, M. M. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000132127.79974.3f · Cited by 213
Self-citation
The VHL tumour-suppressor gene paradigm
Kaelin, W. G., & Maher, E. R. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01558-3 · Cited by 215
Papillary Renal Cell Carcinoma
Corless, C. L., Aburatani, H., Fletcher, J. A., Housman, D. E., Amin, M. B., & Weinberg, D. S. (1996) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199603000-00009 · Cited by 210
The von Hippel-Lindau Tumor Suppressor Gene
Elias, R. M., Zhang, Q. H., & Brugarolas, J. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000480 · Cited by 210
Searching for the hereditary causes of renal-cell carcinoma
Pavlovich, C. P., & Schmidt, L. S. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1364 · Cited by 214
Self-citation
Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31,500-Element cDNA ArrayPreprint
Boer, J. M., Huber, W. K., Sültmann, H., Wilmer, F., von Heydebreck, A., Haas, S., Korn, B., Gunawan, B., Vente, A., FÜZESI, L., et al. (2001) · Genome Research · doi:10.1101/gr.184501 · Cited by 206
von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
Choueiri, T. K., Vaziri, S. A. J., Jaeger, E., Elson, P. J., Wood, L. S., Bhalla, I. P., Small, E. J., Weinberg, V. E., Sein, N., Simko, J. P., et al. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.05.015 · Cited by 201
The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells
Koochekpour, S., Jeffers, M., Wang, P. H., Gong, C., Taylor, G. A., Roessler, L. M., Stearman, R. S., Vasselli, J. R., Stetler‐Stevenson, W. G., Kaelin, W. G., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5902 · Cited by 201
Self-citation
Histological Subtyping and Nuclear Grading of Renal Cell Carcinoma and Their Implications for Survival: A Retrospective Nation-Wide Study of 629 Patients
Guðbjartsson, T., Harðarson, S., Pétursdóttir, V., Thoroddsen, Á., Magnússon, J., & Einarsson, G. (2005) · European Urology · doi:10.1016/j.eururo.2005.04.016 · Cited by 198
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey, C., Martinez, A., Zatyka, M., Agathanggelou, A., Honorio, S., Astuti, D., Morgan, N. V., Moch, H., Richards, F. M., Kishida, T., et al. (2001) · PubMed · Cited by 197
Self-citation
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters
Kondo, K., Yao, M., Yoshida, M., Kishida, T., Shuin, T., Miura, T., Moriyama, M., Kobayashi, K., Sakai, N., Kaneko, S., et al. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10054 · Cited by 202
Cancer Drug Discovery and Development
Humphrey, J. S., Price, K., Gupta, E., Baxter, A. R. W., Bird, J., Sonnichsen, D. S., & Naglich, J. G. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-325-5_21 · Cited by 195
Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
de Paulsen, N., Brychzy, A., Fournier, M.-C., Klausner, R. D., Gnarra, J. R., Pause, A., & Lee, S. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1387 · Cited by 196
Self-citation
Overproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1α Expression in Renal Cell Carcinomas.
NA, X. I., Wu, G., Ryan, C., Schoen, S. R., diSant’Agnese, P. A., & Messing, E. M. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000074870.54671.98 · Cited by 196
Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma
LaGory, E. L., Wu, C., Taniguchi, C. M., Ding, C. C., Chi, J., von Eyben, R., Scott, D. A., Richardson, A. D., & Giaccia, A. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.006 · Cited by 198
Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor Suppressor Protein
Groulx, I., & Lee, S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5319-5336.2002 · Cited by 188
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma
Patard, J., Fergelot, P., Karakiewicz, P. I., Klatte, T., Trinh, Q., Rioux-Leclercq, N. C., SAID, J. W., Belldegrun, A. S., & Pantuck, A. J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23496 · Cited by 193
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky, I. A., Gnarra, J. R., Bertheau, P., Walther, M. M., Linehan, W. M., & Zhuang, Z. (1996) · PubMed Central · Cited by 187
Self-citation
Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications
Walther, M. M., Lubensky, I. A., Venzon, D. J., Zbar, B., & Linehan, W. M. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)66674-6 · Cited by 186
Self-citation
Pazopanib: Clinical development of a potent anti-angiogenic drug
Schutz, F. A. B., Choueiri, T. K., & Sternberg, C. N. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.02.012 · Cited by 185
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
di Meo, N. A., Lasorsa, F. M., Rutigliano, M., Loizzo, D., Ferro, M., Stella, A., Bizzoca, C., Vincenti, L., Pandolfo, S. D., Riccardo Autorino, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214360 · Cited by 182
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Pantuck, A. J., Zeng, G., Belldegrun, A. S., & Figlin, R. A. (2003) · PubMed · Cited by 181
PREVALENCE, MORPHOLOGY AND BIOLOGY OF RENAL CELL CARCINOMA IN VON HIPPEL-LINDAU DISEASE COMPARED TO SPORADIC RENAL CELL CARCINOMA
Neumann, H. P. H., Bender, B., Berger, D. P., Laubenberger, J., Schultze‐Seemann, W., Wetterauer, U., FERSTL, F. J., Herbst, E. W., Schwarzkopf, G., Hes, F. J., et al. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)62509-6 · Cited by 179
Self-citation
Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect
Brauch, H. B., Kishida, T., Glavač, D., Chen, F., Pausch, F., Höfler, H., Latif, F., Lerman, M. I., Zbar, B., & Neumann, H. P. H. (1995) · Human Genetics · doi:10.1007/bf00223868 · Cited by 179
Self-citation
THE ROLE OF THE FHIT/FRA3B LOCUS IN CANCER
Huebner, K., Garrison, P. N., Barnes, L. D., & Croce, C. M. (1998) · Annual Review of Genetics · doi:10.1146/annurev.genet.32.1.7 · Cited by 179
Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
Redman, B. G., Esper, P., Pan, Q., Dunn, R. L., Hussain, H. K., Chenevert, T. L., Brewer, G. J., & Merajver, S. D. (2003) · PubMed · Cited by 178
Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment
Sotgia, F., Martinez‐Outschoorn, U., Pavlides, S., Howell, A., Pestell, R. G., & Lisanti, M. P. (2011) · Breast Cancer Research · doi:10.1186/bcr2892 · Cited by 179
The VHL tumor suppressor: master regulator of HIF
Haase, V. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649394 · Cited by 175
Hypoxia and aging
Yeo, E.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0233-3 · Cited by 175
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Young, A. C., Craven, R. A., Cohen, D. R., Taylor, C., Booth, C., Harnden, P., Cairns, D. A., Astuti, D., Gregory, W. M., Maher, E. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2131 · Cited by 174
Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
Gu, Y., Cohn, S., Christie, A. L., McKenzie, T., Wolff, N. C., Do, Q. N., Madhuranthakam, A. J., Pedrosa, I., Wang, T., Dey, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0292 · Cited by 187
The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth
Schermer, B., Ghenoiu, C., Bartram, M. P., Müller, R., Kotsis, F., Höhne, M., Kühn, W., Rapka, M., Nitschke, R., Zentgraf, H., et al. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200605092 · Cited by 175
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Jin, J., Xie, Y., Zhang, J.-S., Wang, J., Dai, S.-J., He, W., Li, S.-Y., Ashby, C. R., Chen, Z., & He, Q. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100929 · Cited by 185
Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma
Lam, J. S., Shvarts, O., SAID, J. W., Pantuck, A. J., Seligson, D. B., Aldridge, M. E., BUI, M. H. T., Liu, X., Horvath, S., Figlin, R. A., et al. (2005) · Cancer · doi:10.1002/cncr.21127 · Cited by 171
Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor
Elder, E. E., Elder, G. J., & Larsson, C. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20177 · Cited by 171
Genomic profiling in renal cell carcinoma
Dizman, N., Philip, E. J., & Pal, S. K. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0301-x · Cited by 171
Gene expression analysis of renal carcinoma: adipose differentiation‐related protein as a potential diagnostic and prognostic biomarker for clear‐cell renal carcinoma
Yao, M., Tabuchi, H., Nagashima, Y., Baba, M., Nakaigawa, N., Ishiguro, H., Hamada, K., Inayama, Y., Kishida, T., Hattori, K., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1693 · Cited by 170
Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States)
Gago-Domínguez, M., Castelao, J. E., Yuan, J., Ross, R. K., & Yu, M. C. (2002) · Cancer Causes & Control · doi:10.1023/a:1015044518505 · Cited by 170
Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Rini, B. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1989 · Cited by 170
Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status
Messai, Y., Gad, S., Noman, M. Z., Le Teuff, G., Couve, S., Janji, B., Kammerer, S. F., Rioux-Leclerc, N., Hasmim, M., Ferlicot, S., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.029 · Cited by 168
Alterations in VHL as potential biomarkers in renal-cell carcinoma
Gossage, L., & Eisen, T. G. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.42 · Cited by 168
Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.
Eng, C., Crossey, P. A., Mulligan, L. M., Healey, C. S., Houghton, C. A., Prowse, A. H., Chew, S. L., Dahia, P. L. M., O'Riordan, J. L. H., & Toledo, S. P. A. (1995) · Journal of Medical Genetics · doi:10.1136/jmg.32.12.934 · Cited by 167
Molecular Diagnosis and Therapy of Kidney Cancer
Linehan, W. M., Bratslavsky, G., Pinto, P. A., Schmidt, L. S., Neckers, L., Bottaro, D. P., & Srinivasan, R. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.042808.171650 · Cited by 167
Self-citation
HISTOPATHOLOGY AND MOLECULAR GENETICS OF RENAL TUMORS: TOWARD UNIFICATION OF A CLASSIFICATION SYSTEM
ZAMBRANO, N. R., Lubensky, I. A., Merino, M. J., Linehan, W. M., & Walther, M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68259-6 · Cited by 166
Self-citation
Activation of the mTOR Signaling Pathway in Renal Clear Cell Carcinoma
Robb, V. A., Karbowniczek, M., Klein–Szanto, A. J., & Henske, E. P. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.08.076 · Cited by 165
Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low‐risk clear cell renal cell carcinoma
Joseph, R. W., Kapur, P., Serie, D., Eckel‐Passow, J. E., Parasramka, M. A., Ho, T. H., Cheville, J. C., Frenkel, E. P., Rakheja, D., Brugarolas, J., et al. (2013) · Cancer · doi:10.1002/cncr.28521 · Cited by 165

Authors: Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., & Linehan, W. M.
Affiliations: National Cancer Institute (US)
Frederick National Laboratory for Cancer Research (US)
National Institutes of Health (US)
Cornell University (US)
University of Michigan (US)
Technical University of Munich (DE)
Heidelberg University (DE)
Johns Hopkins University (US)
ORCID: Gnarra, J.R.
Schmidt, L.
Wei, M.H.
Lubensky, I.
Bander, N.H.
Brauch, H.
Brooks, J.D.
Isaacs, W.B.
Lerman, M.I.
Linehan, W.M.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1994-05
Volume: 7
Issue: 1
Pages: 85-90
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0594-85
OpenAlex: W2010160635
Cited by: 1,730
References: 29
Citations by year: 2026: 17 · 2025: 25 · 2024: 30 · 2023: 38 · 2022: 38 · 2021: 45 · 2020: 56 · 2019: 47 · 2018: 45 · 2017: 42 · 2016: 57 · 2015: 35 · 2014: 70 · 2013: 66 · 2012: 62
FWCI: 61.77
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: VHL gene, von Hippel-Lindau disease, renal carcinoma, clear cell renal cell carcinoma, loss of heterozygosity
MeSH terms: Base Sequence, Carcinoma, DNA Mutational Analysis, DNA, Neoplasm, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Molecular Sequence Data, Mutation, Organ Specificity, Polymorphism, Restriction Fragment Length, Genes, Tumor Suppressor, Neoplasms, Second Primary, Sequence Deletion, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations of the VHL tumour suppressor gene in renal carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks